Santiago Ramirez, MD
Interventional Cardiology · Tucson, AZNPI 1023096203
Payments from drug & device makers
What this record shows
This record is dominated by other: $32,208 of the $44,989 with a category attached, or 71.6%. Angiodynamics, Inc. accounts for 72.5% of it on its own, with 49 other manufacturers making up the rest. 2025 is the largest year on record at $26,420, more than ten times the $1,717 reported in 2019.
Across 621 payments — averaging $72.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$33K
- Abbott$3K
- Novartis$791
- Boston Scientific$680
- Johnson & Johnson$630
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$612
- plus $6K from 44 others
What the payments were for
- Travel & lodging$3361%
- Food & beverage$12,06227%
- Education$3831%
- Other$32,20872%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$32,330
- remede System$463
- LOKELMA$251
- Edwards SAPIEN 3 Transcatheter Heart Valve$174
- Quadra Assura CRT Defibrillator$156
- Watchman$149
- Barostim Neo System$149
- AVEIR$146
- Navicross$126
- Glidesheath$126
- GlideWire$126
- Vascepa$125
- Fortify Assura$125
- Fortify Assura, Ellipse ICD$109
- HawkOne$104
How this compares
$44,989 in reported general payments places this provider in the 85th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 426 | $534,456 |
| XareltoRivaroxaban | 350 | $415,355 |
| FarxigaDapagliflozin Propanediol | 270 | $279,763 |
| EntrestoSacubitril/Valsartan | 146 | $212,290 |
| JardianceEmpagliflozin | 13 | $21,602 |
| BrilintaTicagrelor | 17 | $20,360 |
| LokelmaSodium Zirconium Cyclosilicate | 17 | $17,567 |
| Repatha SureclickEvolocumab | 12 | $15,470 |
| Metoprolol Succinate | 694 | $11,830 |
| VascepaIcosapent Ethyl | 22 | $11,436 |
| Propafenone Hcl | 108 | $10,286 |
| Icosapent Ethyl | 15 | $8,256 |
| Digoxin | 158 | $7,836 |
| Losartan Potassium | 674 | $7,821 |
| DapagliflozinDapagliflozin Propanediol | 14 | $7,351 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $141 | $534,456426 claims |
| Johnson & JohnsonXarelto | $630 | $415,355350 claims |
| AstraZenecaFarxiga, Brilinta, Lokelma | $500 | $317,690304 claims |
| NovartisEntresto | $791 | $212,290146 claims |
| Boehringer IngelheimJardiance | $217 | $21,60213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Tucson
- Thomas WaggonerTucson$617K
- Kapildeo LotunTucson$365K
- Neil GheewalaTucson$141K
- Dexter de LeonTucson$74K
- William ThomasTucson$56K
- Ranjith ShettyTucson$50K
- Sulaiman RathoreTucson$32K
- Michel CorbanTucson$27K
- Sundeep ShenoyTucson$24K
- Paul SorajjaPhoenix$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.